CY1106223T1 - Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις - Google Patents

Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις

Info

Publication number
CY1106223T1
CY1106223T1 CY20061101554T CY061101554T CY1106223T1 CY 1106223 T1 CY1106223 T1 CY 1106223T1 CY 20061101554 T CY20061101554 T CY 20061101554T CY 061101554 T CY061101554 T CY 061101554T CY 1106223 T1 CY1106223 T1 CY 1106223T1
Authority
CY
Cyprus
Prior art keywords
methods
threonine
protein kinase
function
compounds
Prior art date
Application number
CY20061101554T
Other languages
Greek (el)
English (en)
Inventor
Gerald Mcmahon
Bernhard Kutscher
Eckhard Gunther
Herald APP
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of CY1106223T1 publication Critical patent/CY1106223T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20061101554T 1997-10-06 2006-10-30 Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις CY1106223T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6112397P 1997-10-06 1997-10-06
PCT/US1998/020910 WO1999017759A2 (en) 1997-10-06 1998-10-05 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds

Publications (1)

Publication Number Publication Date
CY1106223T1 true CY1106223T1 (el) 2011-06-08

Family

ID=22033733

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101554T CY1106223T1 (el) 1997-10-06 2006-10-30 Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις

Country Status (30)

Country Link
US (2) US6180631B1 (cg-RX-API-DMAC7.html)
EP (1) EP1028729B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001518496A (cg-RX-API-DMAC7.html)
KR (1) KR100633270B1 (cg-RX-API-DMAC7.html)
CN (1) CN1169527C (cg-RX-API-DMAC7.html)
AR (1) AR013542A1 (cg-RX-API-DMAC7.html)
AT (1) ATE336250T1 (cg-RX-API-DMAC7.html)
AU (1) AU757585B2 (cg-RX-API-DMAC7.html)
BG (1) BG64969B1 (cg-RX-API-DMAC7.html)
BR (1) BR9814814A (cg-RX-API-DMAC7.html)
CA (1) CA2306257C (cg-RX-API-DMAC7.html)
CY (1) CY1106223T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ298775B6 (cg-RX-API-DMAC7.html)
DE (1) DE69835612T2 (cg-RX-API-DMAC7.html)
DK (1) DK1028729T3 (cg-RX-API-DMAC7.html)
ES (1) ES2268791T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0100302A3 (cg-RX-API-DMAC7.html)
IL (2) IL135103A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03011007A (cg-RX-API-DMAC7.html)
NO (1) NO316598B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ503431A (cg-RX-API-DMAC7.html)
PL (1) PL192039B1 (cg-RX-API-DMAC7.html)
PT (1) PT1028729E (cg-RX-API-DMAC7.html)
RU (1) RU2223753C2 (cg-RX-API-DMAC7.html)
SK (1) SK4722000A3 (cg-RX-API-DMAC7.html)
TR (2) TR200000906T2 (cg-RX-API-DMAC7.html)
TW (1) TWI245765B (cg-RX-API-DMAC7.html)
UA (1) UA71555C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999017759A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA988961B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
EP1158985B1 (en) * 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US20040131504A1 (en) * 2002-09-17 2004-07-08 Landers James P. Remote temperature sensing of small volume and related apparatus thereof
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
PT1636228E (pt) * 2003-05-23 2009-02-02 Aeterna Zentaris Gmbh Novas piridopirazinas e sua utilização como moduladores de cinases
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
ATE454152T1 (de) * 2003-06-13 2010-01-15 Novartis Pharma Gmbh 2-aminopyrimidin-derivate als raf-kinase-hemmer
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
WO2007054556A1 (de) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
WO2010003308A1 (zh) * 2008-07-10 2010-01-14 卞化石 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014109414A1 (ja) * 2013-01-11 2014-07-17 富士フイルム株式会社 含窒素複素環化合物またはその塩
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HRP20210319T1 (hr) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije inhibitora fgfr i inhibitora igf1r
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
JP6759514B2 (ja) 2014-08-01 2020-09-23 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ ブロモドメインに対して活性な化合物
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
US12012394B2 (en) * 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001017A (en) * 1972-12-05 1977-01-04 Ciba-Geigy Ag Process for the photopolymerization of ethylenically unsaturated compounds
US4043819A (en) * 1974-06-11 1977-08-23 Ciba-Geigy Ag Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
FR2656606B1 (fr) * 1989-12-28 1993-06-25 Roussel Uclaf Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure.
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
FI935279L (fi) 1991-05-29 1993-11-26 Pfizer Tricykliska polyhydroxyltyrosinkinasininhibitorer
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase

Also Published As

Publication number Publication date
US6180631B1 (en) 2001-01-30
WO1999017759A2 (en) 1999-04-15
KR20010030934A (ko) 2001-04-16
ZA988961B (en) 1999-10-04
CZ20001129A3 (cs) 2000-10-11
IL135103A (en) 2007-06-17
CN1169527C (zh) 2004-10-06
HK1031836A1 (en) 2001-06-29
ES2268791T3 (es) 2007-03-16
IL135103A0 (en) 2001-05-20
NO20001748L (no) 2000-04-05
KR100633270B1 (ko) 2006-10-16
PL339860A1 (en) 2001-01-15
BR9814814A (pt) 2000-10-03
TR200000906T2 (tr) 2000-11-21
JP2001518496A (ja) 2001-10-16
UA71555C2 (en) 2004-12-15
RU2223753C2 (ru) 2004-02-20
AR013542A1 (es) 2000-12-27
NZ503431A (en) 2002-07-26
TR200100385T2 (tr) 2002-06-21
DE69835612T2 (de) 2007-08-16
EP1028729A2 (en) 2000-08-23
WO1999017759A3 (en) 2000-01-06
BG104392A (en) 2000-12-29
PL192039B1 (pl) 2006-08-31
SK4722000A3 (en) 2002-06-04
CN1274284A (zh) 2000-11-22
HUP0100302A3 (en) 2006-03-28
CA2306257A1 (en) 1999-04-15
US6727252B1 (en) 2004-04-27
TWI245765B (en) 2005-12-21
DE69835612D1 (de) 2006-09-28
HUP0100302A2 (hu) 2001-06-28
NO316598B1 (no) 2004-03-01
CA2306257C (en) 2007-09-25
BG64969B1 (bg) 2006-11-30
ATE336250T1 (de) 2006-09-15
CZ298775B6 (cs) 2008-01-23
EP1028729B1 (en) 2006-08-16
PT1028729E (pt) 2006-12-29
NO20001748D0 (no) 2000-04-05
AU757585B2 (en) 2003-02-27
MXPA03011007A (es) 2004-02-27
AU9514198A (en) 1999-04-27
DK1028729T3 (da) 2006-12-11

Similar Documents

Publication Publication Date Title
CY1106223T1 (el) Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις
NO20001555D0 (no) Azabenzimidazolbaserte forbindelser for modulering av serin/treonin proteinkinasefunksjon
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
CY1108567T1 (el) Αντιθρομβωτικες ενωσεις
DE69428290D1 (de) Derivate von alpha-hordothionin mit höherem behalt an lysin
ATE253063T1 (de) 5-ht1f-agonisten
CY1108470T1 (el) Πεπτιδια και πεπτιδομιμητες που εχουν αντι-πολλαπλασιαστικη δραστικοτητα και/ή τα οποια ενισχυουν παραγοντες ή αγωγες που προκαλουν βλαβη στο dna
CY1108688T1 (el) Μυκητοκτονα μειγματα στη βαση ενωσεων αμιδιου
ATE330963T1 (de) Amorphe feste modifikation von bis(2,4- dicumylphenyl) pentaerythritdiphosphit
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
ATE265455T1 (de) Tetrahydropyridoverbindungen
ATE223919T1 (de) Ionische flüssigkeiten, ihre herstellung und ihre verwendung
EA200000519A1 (ru) 2-АРИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
CY1109496T1 (el) Τρυγικο και φωσφορικο αλας της 3,4-διαμινοπυριδινης, φαρμακευτικες συνθεσεις και χρησεις αυτων
EA200000520A1 (ru) 2-АРИЛ-3-АРОИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
DE60210970D1 (de) Mutante formen von etxb und ctxb und ihre verwendung als träger
EA200000522A1 (ru) 5-htагонисты
SE9604582D0 (sv) Novel compounds
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum
DK1001942T3 (da) Polyhydroxybutylpyraziner, deres fremstilling samt medikamenter indeholdende disse forbindelser
PA8478901A1 (es) Isoquinolinas
DK0667863T3 (da) 2-Perhalogenalkyl-substituerede benzimidazoler, deres fremstilling samt deres anvendelse som pesticider
EA200200321A1 (ru) Апоптин-ассоциированный белок